The estimated Net Worth of Suzanne M. Hanlon is at least $302 Thousand dollars as of 6 August 2018. Mr. Hanlon owns over 3,800 units of Zynerba Pharmaceuticals Inc stock worth over $56,801 and over the last 9 years she sold ZYNE stock worth over $0. In addition, she makes $245,039 as Vice President, General Counsel, and Secretary at Zynerba Pharmaceuticals Inc.
Sign up
Mr. Hanlon ZYNE stock SEC Form 4 insiders trading
Suzanne has made over 2 trades of the Zynerba Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 3,800 units of ZYNE stock worth $22,040 on 6 August 2018.
The largest trade she's ever made was buying 3,800 units of Zynerba Pharmaceuticals Inc stock on 6 August 2018 worth over $22,040. On average, Suzanne trades about 850 units every 137 days since 2015. As of 6 August 2018 she still owns at least 43,693 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Hanlon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Suzanne Hanlon biography
Suzanne M. Hanlon J.D. serves as Vice President, General Counsel, Secretary of the Company. Ms. Hanlon served as our legal consultant from May 2014 to October 2014. Ms. Hanlon has more than 25 years of legal experience in the pharmaceutical industry. Ms. Hanlon served as vice president, associate general counsel of NuPathe from July 2005 to April 2014, where she worked with Mr. Anido and Ms. Sebree on the regulatory approval of Zecuity, a transdermal patch for migraines. Prior to joining NuPathe, Ms. Hanlon served as chief development counsel of Auxilium, a specialty pharmaceutical company. Prior to joining Auxilium, Ms. Hanlon served as vice president of global contracts and general counsel at IBAH, Inc. Prior to joining IBAH, Inc., Ms. Hanlon was a partner at Montgomery McCracken Walker & Rhoads LLP. Ms. Hanlon holds a B.A. from Pennsylvania State University and a J.D. from Villanova University School of Law.
What is the salary of Suzanne Hanlon?
As the Vice President, General Counsel, and Secretary of Zynerba Pharmaceuticals Inc, the total compensation of Suzanne Hanlon at Zynerba Pharmaceuticals Inc is $245,039. There are 6 executives at Zynerba Pharmaceuticals Inc getting paid more, with Armando Anido having the highest compensation of $1,369,570.
How old is Suzanne Hanlon?
Suzanne Hanlon is 63, she's been the Vice President, General Counsel, and Secretary of Zynerba Pharmaceuticals Inc since 2018. There are 4 older and 8 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
What's Suzanne Hanlon's mailing address?
Suzanne's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Insiders trading at Zynerba Pharmaceuticals Inc
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici, and Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
What does Zynerba Pharmaceuticals Inc do?
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
What does Zynerba Pharmaceuticals Inc's logo look like?
Complete history of Mr. Hanlon stock trades at Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc executives and stock owners
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Armando Anido,
Chairman of the Board, Chief Executive Officer -
Terri Sebree,
President -
Armando Anido MBA,
Chairman & CEO -
James Fickenscher,
Chief Financial Officer, Vice President - Corporate Development -
Terri B. Sebree,
Pres -
James E. Fickenscher,
CFO, VP of Corp. Devel. & Treasurer -
Suzanne Hanlon,
Vice President, General Counsel, Secretary -
William Roberts,
Vice President, Investor Relations and Corporate Communications -
Pamela Stephenson,
Independent Director -
Kenneth Moch,
Independent Director -
Daniel Kisner,
Independent Director -
William Federici,
Independent Director -
John Butler,
Independent Director -
Warren Cooper,
Lead Independent Director -
Brian Rosenberger,
Vice President - Commercial and Business Development -
Joseph Apostolico,
VP of HR -
Suzanne M. Hanlon,
Sec., VP & Gen. Counsel -
Dr. Joseph Palumbo,
Chief Medical Officer -
Thomas L Harrison,
Director -
Michael Rapp,
10% owner -
Cynthia Ann Rask,
Director -
Albert P Parker,
Chief Legal Officer -
Richard A Baron,
Chief Financial Officer -
Kenneth T Jones,
See Remarks